Inhalation Sciences receives IRS order worth 35,000 Euro from global generics company
Inhalation Sciences AB (ISAB) has received an order from a new client, a global generics company, for an Inhalation Research Services (IRS) project. The client has chosen ISAB’s DissolvIt[®] for the project, due to its outstanding accuracy in testing generic formulations against originator products to define bioequivalence and, potentially, IVIVC (In Vitro In Vivo correlation), both critical metrics in generic drug development.
The new client’s development team are highly expert and experienced in Pharmacokinetics (PK), bioequivalence and dissolution studies. They have chosen ISAB’s simulated in vitro dissolution module DissolvIt® to test the bioequivalence of their generic candidates, due to its accuracy and potential to deliver IVIVC (in vitro in vivo correlated) data.
Bioequivalence is a crucial metric for inhaled generics companies. DissolvIt® is recognized as an advanced solution in the field that can potentially generate IVIVC in vitro data that closely predict later-stage in vivo data, so reducing risk and costs.
CEO Manoush Masarrat: “We are delighted that our technology has been selected by such an expert and experienced team. This is important work and we look forward to working with our new clients. We see good potential here for further projects and collaborations moving forward.”
Read ISAB’s publications on DissolvIt®here.
Discover DissolvIt’s in vitro capabilities here.
Explore Inhalation Research Services here
For more information about Inhalation Sciences, please contact: Manoush Masarrat, CEO E-mail: Manoush.email@example.com Mobile: +46 (0)73 628 9153Press release in PDF format